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1. Introduction
Triiodothyronine (T3) is a primary determinant of normal postnatal somatic growth and
skeletal development, and an important regulator of bone and mineral metabolism in hu‐
man [1, 2]. Before puberty, thyroid hormone appears to be a major prerequisite for normal
maturation of bone [3]. Untreated childhood hypothyroidism results in a profound growth
retardation and a delayed skeletal maturation. In severe cases, linear growth is almost com‐
pletely halted. When treatment occurs, growth often resumes at a rate faster and beyond the
normal rate for age [3, 4]. This phase of accelerated growth constitutes the "catch-up growth"
phenomenon. This may be complete or incomplete depending upon many factors including
the age at presentation, the severity of hypothyroidism and its duration, the age at diagno‐
sis, and the genetic target height.
Thyroid hormones are among the important direct biological regulators of growth plate and
bone accretion. In addition, thyroid hormones influence and interact with the growth hor‐
mone (GH) – Insulin-like growth factor-I (IGF-I) system and other hormones that control
stature and bone growth. Hypothyroid patients show low plasma levels of IGF-I and re‐
duced IGF bioactivity, whereas hyperthyroid patients present high plasma IGF-I levels and
also low IGF bioactivity. [5] Similar changes have been observed in rats [6]. Besides, a de‐
crease in hepatic IGF-I messenger RNA (mRNA) expression in experimental hypothyroid
animals has been reported [7]. In experimental animals the effects of thyroid hormone on
the IGFs system can be GH mediated [11] or non-GH mediated [12-14]. The interrelation‐
ships between the thyroid function and pituitary GH/serum IGFs axis are complex and not
fully understood. GH treatment does not restore serum IGF-I levels in hypothyroid rats [6].
Decreased serum IGF-I levels in hypophysectomized rats increase after treatment with T4
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doses in vivo, in a way significantly greater than after GH administration [15], an effect
which is not observed in vitro, suggesting the presence of factors, other than GH, involved
in the regulation of this axis in vivo.
In human, T4 replacement increases the serum levels of IGF-I and ALS in patients with pri‐
mary as well as central hypothyroidism [16]. Hypothyroidism in childhood is almost invari‐
ably associated with growth failure. After the onset of T4 replacement therapy, growth and
skeletal abnormalities usually resolve and a period of catch-up growth ensues. In the past, it
has been suggested that catch-up growth in children treated for congenital or juvenile hypo‐
thyroidism is complete, and that such children usually reach their expected adult height
[17-21], but this is not supported by recent reports showing a failure of catch-up growth in
children in whom treatment has been initiated after a long period of untreated hypothyroid‐
ism [22-24].
Several mechanisms can contribute to the pathophysiology of growth failure associated with
hypothyroidism. These include: abnormalities of GH secretion, IGF-I synthesis and direct
action of low thyroxine on growth plate and skeletal growth. [16-19, 24, 25]
2. Postnatal Phases of Growth (Infantile-Childhood-Pubertal (ICP)
pattern)
Stature growth is characterized by a pattern of changing height velocity from infancy to
adulthood. A high velocity from birth with a rapid deceleration up to about 3 yr of age is
seen, followed by a period with a lower and slowly decelerating velocity up to puberty.
Puberty starts with an increased velocity and after the age of peak velocity a deceleration is
observed until growth ceases. This pattern of growth is known as the infantile-childhood-
puberty (ICP) pattern. [26-28]
3. Catch-up growth and patterns of catch-up growth
Catch-up growth is the compensatory total increase in the stature growth, either by increas‐
ing the growth velocity and/or by increasing the duration of total growth (delaying growth
plate closure), after correction of the limiting factor that inhibited growth. Catch-up growth
may be complete or incomplete. Catch-up growth is considered to be complete for an indi‐
vidual child if his final height is within the target range. In groups of patients, complete
catch-up growth is expected to result in a mean final height close to the mean target height.
Resumption of a normal height velocity once the growth-suppressing problem has been re‐
solved with a return to and then maintenance of normal height growth velocity (GV) does
not lead to any catch-up growth as the loss in height standard deviation score (HtSDS) is
permanent (not compensated) [26-28].
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3.1. Patterns of catch-up growth
Three different types of catch-up growth can be distinguished: Type A is common in infancy
and early childhood. When growth restriction ceases, height velocity increases up to 4 times
the mean velocity for chronological age in order to compensate rapidly and fully for the
height deficit. Once the original curve is re-approached, height velocity returns to normal. A
classic example of catch-up growth type A occurs after institution of a gluten-free diet in
childhood celiac disease. In catch-up growth type B a small or no increase of height velocity
occurs after the growth restriction has ceased as compared with the mean velocity for chro‐
nological age. However, growth continues for longer than usual, so that ultimately the
growth arrest is compensated. Type C is a mixture of types A and B. When growth restric‐
tion ceases, there is an increase in height velocity as well as a delay and prolongation of
growth. [26-32]
A catch-up process that brings a child to the 50th percentile or above, for a given population
(HtSDS = or > 0) is considered complete. A catch-up that brings a child to > -2 but below 0 is
considered incomplete. Complete catch-up growth may be also accepted when the child at‐
tains a final height within the genetic potential range (Mid-parental height) (+/- 1 SD) [26].
It has been suggested that acceleration of growth velocity rather than delayed maturation
occurs during infancy and early childhood; but during late childhood and adolescence de‐
layed maturation rather than acceleration of growth velocity occurs. This can be explained
by the progressive fall of growth plate chondrocyte proliferation, and hence the reduced po‐
tential for catch-up with age [26-32].
Canalization means that the individual growth curve parallels the percentile curves of
growth charts. In the pre-pubertal period, canalization is clearly seen and therefore a catch-
up growth spurt is easily recognizable. However, during pubertal years, catch-up growth
may not be clearly separated from pubertal growth spurt [26].
4. Regulation of postnatal longitudinal bone growth
Longitudinal bone growth is achieved by the complex, multistep process known as endo‐
chondral ossification, whereby the cartilaginous template of the axial and appendicular skel‐
eton is replaced by bone. This process is initiated when chondrocytes at the epiphyseal
growth plate are stimulated to proliferate and then proceed through stages of maturation
and hypertrophy. In the region of cellular hypertrophy, the surrounding matrix and vascu‐
lar tissue undergo calcification. The hypertrophic chondrocytes degenerate and give way to
invading osteoblasts, and bone and bone marrow subsequently replace the calcified carti‐
lage at the metaphysis. Endochondral ossification is an important determinant of both the
rate and extent of longitudinal bone growth. This growth plate activity is in turn subject to
regulation by a number of factors, which might be of genetic, endocrine, paracrine, and au‐
tocrine origin. It is the complex interactive effects of these substances on chondrocytes in
vivo that determine the final growth response. Endocrine regulators include various hor‐
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mones such as thyroid hormones, GH, parathyroid hormone/parathyroid hormone related
peptide (PTH/PTHrP), as well as several growth factors and cytokines, such as IGF-I and ba‐
sic fibroblast like growth factor. [32-36]
5. Effect of thyroxine on growth plate and bones
Long bones are formed by endochondral ossification and the skull by intramembranous os‐
sification. During endochondral ossification, mesenchyme-derived chondrocytes form a car‐
tilage model, undergo hypertrophic differentiation and then apoptose. The surrounding
collagen X-rich cartilage matrix calcifies and forms a scaffold for bone formation by osteo‐
blasts. Organized columns of proliferating and differentiating chondrocytes persist in the
growth plate until adolescence and mediate linear growth and the acquisition of peak bone
mass. The epiphyses and metaphyses of long bones originate from separate ossification cen‐
ters that are separated by a growth plate. By contrast, in intramembranous ossification, os‐
teoblasts differentiate from mesenchyme to form bone directly. Adult bone structure and
mechanical strength are preserved by a continuous process of skeletal remodelling during
which precise coupling of osteoclastic bone resorption and subsequent osteoblastic bone for‐
mation is maintained. [37]
Hypothyroidism slows longitudinal bone growth and endochondral ossification, while hy‐
perthyroidism accelerates both processes. In hypothyroid animals, there is a decrease in the
heights of the proliferative and hypertrophic zones, and a decrease in chondrocyte prolifera‐
tion and chondrocyte hypertrophy and disruption of the normal columnar organization of
the growth plate and vascular/bone cell invasion. T3 seems to stimulate the recruitment of
cells to the proliferating zone from the germinal zone and facilitate the differentiation of
growth plate chondrocytes. [38,39] In thyroid receptor (TRa) knockout mice [40] there is a
complete growth arrest, with disorganization of epiphyseal growth plate chondrocytes and
delayed cartilage mineralization and bone formation. These abnormalities result from severe
hypothyroidism due to impaired thyroid hormone production at weaning, as the skeletal
phenotype can be rescued by T4 replacement. [40] In the hypothyroid rat, proliferating
chondrocytes fail to form discrete columns and the hypertrophic zone is diminished in
width and morphologically indistinct. Expression of collagen X, a specific marker of hyper‐
trophic chondrocyte differentiation is undetectable in the hypothyroid growth plate, indicat‐
ing that hypertrophic chondrocyte differentiation is severely impaired.
The growth plate is separated from the primary spongiosum by a mineralised interface, es‐
sentially sealing off the growth plate from vascular invasion and preventing further bone
lengthening, leading to growth retardation. During hypothyroidism, there is disruption of
the normal functional continuity between maturing chondrocytes and mineralizing osteo‐
blasts with markedly reduced osteoblast invasion and fewer, thinner bone trabecula. T4 in‐
duces the expression of both type II and X collagen, the activity of the differentiation marker
alkaline phosphatase, and chondrocyte hypertrophy. [38-40]
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In addition, the growth plates of hypothyroid rats also have abnormal cartilage matrix depo‐
sition. Normal cartilage matrix is composed of proteoglycans containing chondroitin and
heparan sulfates and hyaluronic acid residues. In hypothyroid rats, studies have revealed an
abnormal increase in sulfation of heparan sulfate proteoglycans in proliferating chondro‐
cytes. This abnormal matrix is deposited in a patchy irregular fashion suggesting that thy‐
roid hormones influence extra-cellular matrix biology as well as cellular activity of the
growth plate. Treatment of these rats with thyroid hormones reverses these changes and
studies have shown that this is through the direct actions of T3 on bone, and it is not growth
hormone (GH) mediated [38]. T4 but not GH is capable of completely reverting reduced
widths of the proliferating and hypertrophic zone, as well as a disturbed growth plate archi‐
tecture and vascular invasion of the growth plate in hypothyroid rats, establishing a unique
role for thyroid hormones in the regulation of bone growth and maturation [39- 44].
In vitro, thyroid hormones also stimulate terminal differentiation of epiphyseal growth plate
chondrocytes. [45] Tibial dyschondroplasia (TD), a disorder of broiler chickens, associated
with avascular non-mineralised cartilage extending from the epiphyseal growth plate, re‐
sults from the inability of proliferating chondrocytes to undergo terminal differentiation to
hypertrophic chondrocytes. This disorder has been shown to be associated with a markedly
reduced expression of iodothyronine deiodinase type 2 (DIO2) in the growth plate [14].
DIO2 acts by catalysing the conversion of T4 to T3. Epiphyseal dysgenesis ( Figure 3) in hy‐
pothyroidism can be similarly explained by a reduction in T3 which is necessary to stimu‐
late resting zone cells to proliferate and differentiate into chondrocytes, and for vascular
invasion of the growth plate [46, 47].
Indian hedgehog (Ihh) is a member of the hedgehog family of secreted ligands and is a mas‐
ter regulator of bone development. Ihh is synthesized by prehypertrophic and hypertrophic
chondrocytes [48, 49]. Ihh stimulates production of parathyroid hormone-related peptide
(PTHrP) from cells at the periarticular ends of bones. PTHrP acts on the PTH/PTHrP recep‐
tor (PPR) to keep proliferating chondrocytes in the proliferative pool. When the source of
PTHrP is sufficiently distant, the chondrocytes are no longer stimulated by PTHrP and they
stop proliferating and start to synthesize Ihh. In addition, Ihh stimulates chondrocyte prolif‐
eration directly and also controls the differentiation of osteoblasts from perichondrial cells
during the formation of the bone collar. Thus, interactions between Ihh and PTHrP deter‐
mine the lengths of proliferating columns of chondrocytes in the growth plate and hence the
pace of bone growth. In hypothyroid animals Ihh is mainly located within the upper regions
of the proliferative zone and the reserve zone [50]. PTHrP mRNA expression is also altered
in the hypothyroid growth plate. Levels of expression are increased and include expression
by chondrocytes extending throughout the proliferative and reserve zones. PTH/PTHrP re‐
ceptor (PPR) is also altered by thyroid status. It is expressed throughout all zones of the
growth plate in euthyroid and hypothyroid animals, and restricted to proliferative and pre‐
hypertrophic chondrocytes in hypothyroid-T4 treated rats. Thyroid hormone has been
shown to stimulate terminal differentiation of growth plate chondrocytes by down regula‐
tion of Sox9, a transcription factor present in cells of mesenchymal condensations and prolif‐
erating chondrocytes but not in hypertrophic chondrocytes [51]. This terminal
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differentiation process is associated with expression of cyclin-dependant kinase inhibitors
known to regulate the cell cycle checkpoint [52].
These data strongly support a role for thyroid hormones in regulating components of the
Ihh/PTHrP feedback loop in the growth plate and thus the pace of chondrocyte differentia‐
tion and bone growth.
Fibroblast Growth Factor Receptor-1 (FGFR1) is a T3-target gene in bone. Three FGFRs are
known to be essential for skeletal development. Mutations of all three FGFRs can cause vari‐
able bony abnormalities, while an activating mutation of FGFR3 is the cause of achondropla‐
sia, the most common genetic form of dwarfism [53, 54]. FGFR1 has been identified as a T3-
target gene in osteoblasts [55]. T3 acting via the thyroid hormone receptor (TR) enhances
FGF stimulation of FGFR1 activity. Hypothyroid mice display delayed endochondral ossifi‐
cation and have abnormalities of cartilage matrix similar to those described above, namely
an increase in heparan sulfate proteoglycans [54]. It is known that heparan sulfate is re‐
quired for binding of FGF to FGFR and for ligand-induced receptor activity [56, 57]. There‐
fore, T3-regulated production of heparan sulfate, or modification of its structure, might be
the mechanism by which T3 regulates FGFR1 signalling. In addition to the thyroid hormone
receptors, receptors for growth hormone (GH), insulin like growth factor-1 (IGF-1), are also
expressed by growth plate chondrocytes [58-60]. T3 influences expression of several compo‐
nents of GH/IGF-1 signalling in bone [61, 62].
Figure 3. Effect of thyroxine treatment on infants and children with congenital hypothyroidism (CH) (infantile and
childhood phases) growth diagnosed through neonatal screening compared to their mid-parental height (MPHtSDS).
In summary, thyroid hormones act through chondrocytes bearing TRs to modulate growth
plate proliferation, differentiation, and vascular invasion. These functions are mediated via
many possible mechanisms including direct action on the chondrocytes, osteoblasts and
mast cells, as well through interaction with other hormones and growth factors acting in en‐
docrine, paracrine and autocrine fashions. Understanding the mechanisms behind the inter‐
actions between the T3 signaling pathway and the systemic and paracrine effects of GH/
IGF-1 is important in considering the molecular biology of thyroid hormone-dependent
skeletal development.
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6. Effect of hypothyroidism on bone remodelling and skeleton
Remodelling is crucial for bone health, which is characterized by simultaneous formation
and resorption. Thyroid hormones affect bone cells both in vitro and in vivo by stimulating
osteoblast and osteoclast cells with more bone resorption and increased skeletal remodel‐
ling. Thyroid hormone status within the physiological range affects bone mass and density.
In healthy men at age of peak bone mass, between-subject variation in thyroid hormone con‐
centrations affects bone density. Higher levels of FT3, TT3, TT4 and TBG are associated with
less favourable bone density and content [63-65].
In experimental adult dogs, thyroxine administration in moderate pharmacologic doses in‐
creased the activation frequency, number of bone-forming and -resorbing sites, and the os‐
teoid seam circumference in unaltered bone. Thyroxine, by activating skeletal remodelling,
increases bone turnover and both formation and resorption at the tissue level. The increased
serum calcium and phosphorus levels and urinary hydroxyproline excretion at several inter‐
vals during thyroxine administration are consistent with the morphometric evidence of in‐
creased bone turnover and resorption. These findings suggest that thyroxine is a potent
activator of skeletal remodelling. [66]
In sheep, thyroidectomy at 105-110 days of gestation results in very low levels of foetal plas‐
ma T4 and T3 (no pre-partum rise in fetal plasma T3) and the foetuses have shorter bones
and altered metatarsal structure and strength when analysed at or close to term (145 ± 2
days). At and just before term the thyroidectomised sheep data indicated that the structural
changes in bone are a result of impaired bone formation whilst resorption was normal.
These changes resemble the phenotype reported in adult D2 knockout mice but the precise
cellular basis is not known [67]. The reduced bone formation may be a consequence of local
effect of T3 on the bones or due to altering signalling pathways such as the GH/IGFI axis
which is known to be anabolic to the skeleton.
In human, overt hyperthyroidism is associated with increased bone resorption, low bone
mineral density and increased number of fractures in postmenopausal women [68-70]. Both
hyperthyroidism and to some extent hypothyroidism are linked to reduction of bone miner‐
al density and, hence, increased risk for fracture. Low thyroid hormone levels, rather than
the increased TSH levels, are responsible for the decreased bone resorption during hypo‐
thyroidism in thyroid carcinoma patients. The levels of C-cross linking terminal telopeptide
of type 1 collagen were lower during hypothyroidism compared to 8 weeks after reinstitu‐
tion of thyroxine replacement therapy [71,72].
Clinically, the radiological skeletal manifestations of congenital and severe juvenile hypo‐
thyroidism include:
a. in the long bones: delay in the appearance of ossification centres (delayed bone age), de‐
formed and irregular shape (epiphyseal dysgenesis) of the already existing centres and
metaphyseal widening (splaying);
b. in the skull: the presence of the intrasutural (wormian) bones, widening of the sutures
and fontanelles, delayed closure of fontanelle and delayed teeth eruption,
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c. in the vertebrae : abnormal flattening, bulleting and inferior lipping and
d. broadening of ribs [73,74].
These radiological changes appeared similar in many aspects to those reported in mucopo‐
lysaccharidosis (MPS) and can be explained by the previously mentioned abnormalities in
the growth plate chondrocytes, bone cells and matrix [72,75] (Figure 3).
7. Effect of thyroxine on Growth hormone-Insulin-like growth factor-I
system
In addition to its local action on the growth plate, thyroid hormones may have indirect ef‐
fects on the growth plate, mediated by GH and IGF-I. In hypothyroid humans and mice, GH
and IGF-I levels are reduced and IGF-I generation is defective. In addition to the local action
of thyroxine on growth plate, treatment with thyroxine increases IGF-I secretion and im‐
proves IGF-I generation associated with increased growth rate. Moreover, thyroid hormones
have been shown to interact with the GH-IGF-I pathway at the level of the growth plate. T3
was shown to promote proliferation of embryonic chicken chondrocytes and cultured rat ep‐
iphyseal chondrocytes by enhancing IGF-I mRNA expression. T3/T4 can regulate growth
hormone receptor (GHR) expression, in vivo in rat growth plates [75-77].
The effects of T3 and IGF-I on (3H) thymidine incorporation, alkaline phosphatase (ALP) ac‐
tivity and IGF-I receptor mRNA levels are studied in rat epiphyseal chondrocytes cultured
in monolayer. ALP activity (a late marker of differentiated epiphyseal chondrocytes) is in‐
creased by T3 in a dose-dependent manner with a maximal response at 10 micrograms. IGF-
I receptor mRNA levels were increased by 10 micrograms of T3 while no effect of hGH (50
micrograms/l) or IGF-I (25 micrograms/l) was demonstrated. Both T3 and IGF-I are shown
to interact with epiphyseal chondrocytes and both substances seem to affect cell prolifera‐
tion and maturation and therefore longitudinal bone growth. These results indicate that
IGF-I is important for proliferation of the cells while T3 initiates the terminal differentiation
of epiphyseal chondrocytes [78].
In children with hypothyroidism Soliman et al. [73] have reported a significant decrease of
GH response to Clonidine stimulation as well as a decreased IGF-I generation in response to
GH stimulation. IGF-I generation shows a small but significant increase in the IGF-I produc‐
tion in response to the exogenous GH. The mean peak is lower than 100 ng/ml, which is the
cut off to define GHD stated in the normative data. [73]. This limited, yet significant IGF-I
generation after GH administration suggests that the GHD associated with the hypothyroid
state was not the sole explanation to the low IGF-I level and supports the possibility of associated
GH insensitivity (GHI) state and/or a direct role of thyroxine on hepatic IGF-I production not
mediated via GH. In hypothyroid patients, after treatment with thyroxine, marked improve‐
ment in the IGF-I generation occurs but this is still lower compared to normal children. Cavaliere
H et al. [79] have found significantly decreased basal IGF-I concentrations in primary hypo‐
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thyroid and endemic cretins with a significant increase after treatment and have described a
positive correlation (r = 0.56) between IGF-I and serum T4 and T3 concentrations.
In the mature hypothyroid rats, serum IGF-I levels are partially corrected by GH but are
normalised by thyroid hormone replacement [80].
Gaspard T et al. [81] reported that the administration of T4 alone to hypophysectomized or
thryoidectomized animals was capable of stimulating the IGF-I activity in the absence of
GH. Romos S et al., [82] reported good positive correlation between IGF-I and thyroid hor‐
mone concentrations in both neonatal and adult thyroidectomized rats and that the correla‐
tion between them was dependent on the dose of T4. Also, Ikeda T et al. [83] stated that the
T3, but not T4, directly enhances the release and synthesis of IGF-I in a dose dependent
manner in the rat liver. T3 also controls the IGF-I biosynthesis in nerve cells in rats [84]. Col‐
lectively, the effects of thyroid hormone on serum IGF levels seem to be mediated only par‐
tially via GH but other effects involving either direct thyroid hormone effects, or mediated
by some other route, independent of GH, appear to be working.
In children with hypothyroidism, in spite of significant improvement of IGF-I levels after
treatment versus before treatment, IGF-I generation is still significantly below age-matched
normal children. This defective IGF-I production after treatment suggest that prolonged hy‐
pothyroidism may modulate the IGF-I secreting ability of the hepatocytes either through
negative effect on their mass (number or size) and/or on the expression of the GHR on their
surfaces. In sheep, induction of the hepatic GH receptor and the maturational switch in hep‐
atic IGF-I synthesis are initiated by the pre-partum rise in foetal plasma cortisol [85,86]. Cor‐
tisol also stimulates deiodination of thyroxin (T4) to triiodothyronine (T3) and thereby leads
to a pre-partum rise in plasma T3 that coincides with the increase in hepatic GH receptor
and IGF-I gene expression toward term [86].
Figure 1. Photograph of patient demonstrating her coarse facial features before treatment [11 years] and improve‐
ment after treatment.
Forhead AJ et al., [87] have reported that thyroid hormones regulate hepatic growth hor‐
mone receptor (GHR) and IGF-I gene expression in the sheep fetus during late gestation.
Thyroid hormone deficiency induced by foetal thyroidectomy abolished the normal pre-par‐
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tum rise in hepatic GHR mRNA abundance. However, the precise mechanisms by which T3
acts on the GHR gene are unclear [88]. Nuclear thyroid hormone receptors are present in foetal
ovine liver during late gestation and have a 10-fold greater affinity for T3 than T4 in utero [89].
The effect of thyroid hormone on the regenerative capacity of hepatocytes may be impor‐
tant. Moro L et al. [89] and Alisi A et al., [90] have proved the role of thyroid hormones on
the regenerative capacity of the liver which was reduced during the hypothyroid state and
regained to normal after thyroid hormone administration through altering the expression of
the proteins involved in the control of cell cycle and apoptosis, decreasing tissue rate of pro‐
tein synthesis, and retarding growth of the liver and the whole animal [91, 92]. These studies
propose an important role of thyroid hormones on the hepatocyte regenerative power and
the GHR expression on hepatocytes and suggest that thyroxine deficiency may compromise
these functions and dependent loss of IGF-I production capacity.
In adults with GH deficiency, GH administration stimulates peripheral T4 to T3 conversion
in a dose-dependent manner. Serum T3 levels are subnormal despite T4 substitution when
the patients are off GH but normalised with GH therapy. Energy expenditure increases with
GH and correlates with free T3 levels. GH causes a significant blunting of serum TSH. These
findings suggest that GH plays a distinct role in the physiological regulation of thyroid
function in general, and of peripheral T4 metabolism in particular [93].
Untreated primary hypothyroidism is associated with decreased GH pulsatility, attenuation
of GH response to secretagogues and a reduction in IGF-I and IGF Binding Protein-3 (IGFBP-3).
Reduced levels of IGF-I that increase with L-thyroxine replacement therapy have also been
demonstrated in the setting of subclinical hypothyroidism [94,95]. Conversely, hyperthyroid‐
ism is associated with an increase in mean 24 hour GH concentration and secretion rates [96,
97] while serum IGF-I and IGFBP-3 levels have been found to be normal in subclinical hyper‐
thyroidism [84] with a normal or high [94, 98, 99] IGF-I in overt thyrotoxicosis. Administra‐
tion of T4 to hypophysectomised animals has been shown to stimulate IGF-1 production in
the absence of GH, while IGF-BP3 was shown to be GH dependent [100].
In summary, thyroid hormones modulate growth plate growth and part of this effect ap‐
pears to be mediated by activating GH-IGF-I axis and modulating local GH and/or IGF-I actions.
8. Thyroxine and catch-up growth
Evidence from animal studies suggests that catch-up growth is due, in large part, to a delay
in growth plate senescence. Growth plate senescence refers to the normal, programmed
changes that occur in the growth plate over time i.e. growth plate chondrocytes may have a
finite proliferative capacity that is gradually exhausted, causing growth to slow and eventu‐
ally to stop. With increasing age, there is a decrease in the linear growth rate, the chondro‐
cyte proliferation rate, the height of the growth plate, and the number of cells in each
growth plate zone. Growth plate senescence is not a function of time per se, but of cell pro‐
liferation. Hypothyroidism suppresses growth plate chondrocyte proliferation, but it con‐
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serves the proliferative capacity of the chondrocytes and therefore it slows their senescence.
Consequently, after transient growth inhibition, growth plates retain a greater proliferative
capacity, are less senescent, and, hence, show a greater growth rate than expected for age,
resulting in catch-up growth [101,102].
Marino R et al. [102] have administered propylthiouracil to newborn rats for 8 wk to in‐
duce hypothyroidism and then stopped the propylthiouracil to allow catch-up growth. In
untreated controls, the growth plates undergo progressive, senescent changes in multiple
functional and structural characteristics. In treated animals, after stopping propylthioura‐
cil,  these functional,  structural,  and molecular  senescent  changes are delayed,  compared
with controls. This delayed senescence includes a delayed decline in longitudinal growth
rate, resulting in catch-up growth. These findings demonstrate that growth inhibition due
to hypothyroidism slows the developmental program of growth plate senescence, includ‐
ing the normal decline in the rate of longitudinal bone growth, thus accounting for catch-
up growth.
A proportion of patients with T3 resistance, caused by mutant T3 receptor proteins, suffer
from growth retardation and developmental abnormalities of bone [103,104] that reflect tis‐
sue hypothyroidism. T4 replacement induces rapid catch-up growth, although this may be
incomplete because bone age advances faster than the increase in height [105].
The deficit in final height after treatment appears to correlate with the severity and duration
of hypothyroidism. Catch-up growth may be especially compromised if treatment is re‐
quired at or around the onset of puberty. Boersma B et al, [106] reported that if catch-up
growth coincides with the pubertal growth spurt, final height might be compromised, possi‐
bly due to very rapid bone maturation. Soliman et al. [73] found that treatment of elder chil‐
dren with neglected hypothyroidism accelerates their bone maturation in the first year of
treatment (bone age delay changed from 4.7 +/- 1 years to 3.1 +/- 0.9 years after a year of
therapy). In accordance with this, childhood thyrotoxicosis causes accelerated growth and
advanced bone age, which may lead to craniosynostosis, premature growth plate closure,
and a short stature [107].
9. Growth in Congenital and Juvenile Hypothyroidism Before Versus
After Thyroxine Treatment
Poor length growth is apparent as early as the first year of life. Before the neonatal screening
was initiated in the 1970s, the percentage of children with congenital hypothyroidism (CH)
having a height below the 10th percentile has been shown to range from 19% to 31%. Adult
stature without treatment ranges from 1 to 1.6 metres, depending on severity, sex and other
genetic factors. Bone maturation and puberty are severely delayed. Ovulation is impeded
and infertility is common. Growth arrest, delayed bone age, and epiphyseal dysgenesis oc‐
cur in congenital hypothyroidism, juvenile hypothyroidism and in some patients with resist‐
ance to thyroid hormone, whereas accelerated growth and skeletal maturation are evident in
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childhood thyrotoxicosis [108-109]. Catch-up growth during thyroid hormone replacement
treatment is marked but, unfortunately, may not be complete.
In animals, the dose-response relationship between thyroid hormone and linear growth, has
been studied in prepubertal methimazole-induced hypothyroid monkeys. Subsequently,
each animal has received 1, 2, 4, or 8 micrograms/kg per day of T4, IM, for 9 weeks. Methi‐
mazole administration decreases thyroid hormone and IGF-I levels and decreases leg
growth rate. With increasing doses of exogenous T4, serum T4, T3, and IGF-I as well as low‐
er leg growth rate increase significantly. Animals not given T4 has a 65% decrease in lower
leg growth rate. Animals given 4 and 8 micrograms/kg per day T4 have 56% and 73% in‐
creases, respectively, in lower leg growth rate compared to baseline. Lower leg growth rate
correlate better with serum T3, T4 and IGF-I. Serum IGF-I correlate with serum T3. This
study proves that increased serum T4 and T3 levels cause progressive increases in growth
velocity and IGF-I levels over a range from moderate hypothyroidism to moderate hyper‐
thyroidism. Growth velocity and IGF-I levels correlate more strongly with the serum T3
than with the serum T4 level. [110]
In humans, many case studies and clinical research papers have investigated linear growth
and pubertal maturation in neglected hypothyroidism. Their results can be summarised as
following:
Case Report: An 11 year- old Egyptian girl has presented with severe short stature and men‐
tal retardation. Examination has revealed all features of cretinism with Height SDS (HtSDS)
= -7.6 SD, hypotonia, umbilical hernia, myxedematous face, and severe mental retardation
with IQ = 30. Low T4 and high TSH (Figure 1, Table 1) with bone age of 4 years are noted
with marked epiphyseal dysgenesis, metaphyseal and vertebral changes. L-thyroxine thera‐
py for ten years has been associated with significant and prolonged catch-up growth till the
age of 20 years with near-normal adult stature compared to mid-parental height HtSDS =
-0.9. Puberty started at the age of 15 y and progressed over 4 years to full maturity. All radi‐
ological skeletal abnormalities were corrected after 5 years of thyroxine therapy. Significant
increase in IGF-1 level and IGF-I response to GH stimulation was achieved early. In summa‐
ry, complete catch up of growth with normalization of all radiological changes could occur
even in neglected congenital hypothyroidism.
Age
[y]
Bone age [y] HtSDS GVSDS T4
ug/dl
TSH
mIU/ml
IGF-I
ng/dl
Birth ND 0 ND ND ND ND
11 3 -7.6 3.4 0.5 "/100 25
12 6 -7.2 2 14.7 0.5 75
14 10 -6.5 6 14.00 0.6 98
16 12 -4.6 7 13.8 0.5
18 14 -2.9 7 12.5 0.5
20 16 -1.6 ND 13.9 0.8
Table 1. Growth and hormonal data of a patient with neglected hypothyroidism before and after treatment for 9
years.
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Kubicky et al. have described a patient who discontinued treatment few months for 3 years
after neonatal diagnosis, and although treated till puberty she had significant growth retar‐
dation as an adult. Boersma et al. have described two children with untreated congenital hy‐
pothyroidism, and although they have experienced a marked catch-up growth, both of them
have reached an adult height below their target height [106, 110].
Soliman et al. [73] have studied 15 children with neglected hypothyroidism aged = 6.4 +/- 4.2
years. Patients had HtSDS = -4.3 +/- 2.5 and delayed bone age (– 4.5 +/- 2), with defective GH
response to clonidine and low IGF-I concentration. After two years of treatment with L-thy‐
roxine, their HtSDS has increased from -4.3 +/- 2.5 to -2.7 +/- 2.3. This has been associated
with a significant improvement of their GH response to clonidine, increased IGF-I genera‐
tion in response to GH stimulation. HtSDS increments correlated significantly with free T4
concentrations, and the growth velocity standard deviation score (GVSDS) s correlated sig‐
nificantly with increments in IGF-I concentrations with treatment. Therefore, in neglected
hypothyroidism permanent height loss could not be prevented. The capacity to establish a
significant, although incomplete, catch-up growth spurt is associated with significant recov‐
ery of GH -IGF-I axis and is proved to be possible, even after a long period of thyroid dys‐
function. Incomplete catch-up growth after delayed treatment of infants and children with
congenital hypothyroidism has been reported in other studies [73,111].
In a retrospective study of 59 children with late diagnosis of hypothyroidism presented at
different ages in the Endocrinology clinic of Alexandria University before the establishment
of neonatal screening national program, Soliman et al. measured the HtSDS of patients be‐
fore versus after 2 years of treatment. Results showed significant catch-up growth in those
diagnosed during the first two years of life compared to those diagnosed after 6 years of life
(Figure 2). Pubertal maturation was delayed in 10/21 patients and accelerated in 3/21. (Un‐
published data by authors) (Table 2)
Figure 2. Height Standard Deviation Score [HtSDS] before [dark blue] and after [light blue] one year of treatment of
neglected cases of hypothyroidism diagnosed at different ages.
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Delayed Puberty Normal Puberty Precocious Puberty
Males [n = 9] 6 2 1
Females [ n = 12] 4 6 2
Total [ n = 21] 10/21 8/21 3/21
Table 2. Pubertal Data in neglected hypothyroidism
Collectively, these studies demonstrated clearly the deleterious effect of hypothyroidism on
all stages of growth [infantile, childhood and pubertal phases] and the incomplete catch-up
growth after treatment with thyroxine especially in older children.
10. Growth in Congenital hypothyroidism treated at the neonatal period
Forty years after the worldwide introduction of neonatal screening for congenital hypothyr‐
oidism, it is beyond doubt that early diagnosis and thyroxine treatment prevent brain dam‐
age. Although benefits of early treatment have never been proven in randomized placebo-
controlled trials, studies that described the natural course of congenital hypothyroidism are
considered sufficient evidence for its efficacy, at least in severe forms [73, 111-114]. After the
introduction of the screening, several studies have reported a normal linear growth in infan‐
cy and childhood [115-117], while others have described a slight growth deceleration early
in childhood in children with severe CH at diagnosis [118-120]. With respect to the achieve‐
ment of a normal final height, some studies have suggested that the adequacy of L-thyro‐
xine replacement in the first 6 months of life may influence the adult height of children with
CH detected by newborn screening [121]. In contrast, other studies have found no correla‐
tion between severity at diagnosis, aetiology, or initial L-thyroxine dosage [122,123]. The on‐
ly postnatal factor consistently found to be related to adult height has been the age at the
start of treatment.
Salerno et al. [122] reported normal linear growth and onset and duration of puberty in both
males and females (n= 55) with congenital hypothyroidism (CH) detected by a neonatal
screening program and treated with thyroxin. Their data have shown that the onset and the
progression of puberty are independent of the aetiology, the severity of CH and the timing
of the beginning of treatment. Girls treated with an initial amount of L-thyroxine (L-T4) > 8
microg/kg per day have shown an earlier onset of puberty compared with girls treated with
a lower initial dose of L-T4. However, both groups have attained a similar final height,
which in both cases was above the target height. No significant relationship has been found
between final height and severity of CH at diagnosis, initial L-T4 dosage or aetiology of hy‐
pothyroidism.
Soliman et al. [124, 125] have reported that hypothyroid patients (n =45) diagnosed through
the neonatal screening program have normal birth length, weight and head circumference
compared to normal infants. These data rule out significant effect of foetal hypothyroidism
on foetal growth. When treated with an initial T4 dosage (50 ug/day) with adjustment of T4
dose to maintain serum fT4 concentrations within the upper quartile of normal range and
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TSH < 4 mIU/ml, these children have adjustment (+/- 0.5 SD) of their mean HtSDS towards
their mid-parental height SDS (MPHtSDS) only during the second year of life. In addition,
child mean HtSDS is higher than MPHtSDS by an average of 0.4 SD between the 2nd and 8th
year of life (Figure 3). Adachi et al. [126] have reported normal adult height of patients with
CH detected by neonatal screening which was equivalent to that of the reference population
and their target height.
Figure 4. A: Skull X ray, lateral views, in a two- year-old child and 18-months old child demonstrating persistent wide
anterior fontanelle, mild degree of brachycephaly in a relatively underdeveloped skull base with increased bone densi‐
ty, underdeveloped paranasal sinuses and slightly hypoplastic facial bones, enlarged sella turcica (Cherry sella), few
wormian bones along lambdoid suture, relatively narrowed deploic space of parietal bones and overcrowded teeth.
B : AP view of knee demonstrating epiphyseal dysgenesis [irregularity and mild stippling] of the lower femoral and
upper tibial epiphyses which are relatively small; and a delayed appearance of the upper fibular epiphysis for age of
the patient. C, D. Plain X ray of the pelvis and both hips in a two-year-old child (C ) and five-year-old (D ) demonstrat‐
ing epiphyseal dysgenesis of the upper femoral epiphyses (irregular flattened upper femoral epiphysis which are small
for age of the patient;underdeveloped) with relatively shallow acetabular roofs and mild coxa vara deformity and rela‐
tively small (hypoplastic) iliac bones. E,F : Plain X ray of dorsolumbar region of two different patients demonstrating
flattening of the vertebral bodies with relative osteoporosis leading to the appearance of "picture framing" of verte‐
bral bodies (E, and relatively wide disc spaces with typical bullet shape appearance of vertebral bodies (LV1 and LV2 )
and relatively small body of LV1 with anterior subluaxation of DV12 over LV1 leading to smooth gibbus deformity (F).
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Dickerman and de Vries [127] have found normal prepubertal and pubertal growth and ach‐
ievement of normal adult height in children diagnosed through neonatal screening (n = 30)
and have reported a significant correlation with parental height and the mean L-T4 daily
dose administered over the first 6 months of treatment. A dose of at least 8.5
micrograms/kg/day is recommended by these authors during this period.
Jones et al. [128] have studied growth of 314 CH children according to initial daily dose of
T4: Group 1 (25 ug, n = 152), Group 2 (30-40 ug, n = 63) and Group 3 (50 ug, n = 99). At 3
months weight, length and OFC SDS values have been (-0.39, -0.35, 0.09); (-0.30, -0.47, 0.32) ;
and  (-0.03,  -0.13,  0.18)  for  Groups  1,  2  and  3,  respectively,  indicating  no  difference  be‐
tween the 3 doses on somatic growth between 3 months and 3 years. However, an initial
T4 dose of 50 ug daily has normalized thyroid function several months earlier than lower-
dose regimes. These data has been confirmed by Salerno et al. [129] who have reported that
higher dose has been shown to improve the IQ at 4 years of age,  even in patients with
severe CH at diagnosis.
These results suggest that conventional management of children with CH detected by neo‐
natal screening with an initial dose > 8 ug/kg/day leads to normal infantile, childhood and
pubertal growth with normal adult height and sexual development, and that the major fac‐
tors determining adult height in these children are the familial genetic growth potential and
good compliance to treatment. However, a still unsolved question is whether neonates with
mild hypothyroidism benefit from treatment, too [130-134].
11. Growth before and after Juvenile-Acquired hypothyroidism:
In one study, hypothyroidism has been diagnosed and treated in 18 girls and six boys with
prolonged juvenile hypothyroidism with a mean age of approximately 10.5 years and bone
age = 6.1 years. At diagnosis, the HtSDS scores are -4 +/- 0.5 in boys and -3.12 +/- 0.5 in girls.
Treatment up to achieving the final adult has demonstrated incomplete catch-up (HTSDS =
-2.1 +/- 0.2) with loss of 6-7 cm of the predicted adult height. Delay in therapy has been a critical
factor in the deficit in the final adult height [138]. Another study following 20 girls and 9 boys
with juvenile primary hypothyroidism until  they reached final height has shown that at
presentation the mean age of the boys was 9.5 years (bone age = 6.3 years) and mean age of
girls was 8.8 years (bone age= 5.4 years). In the girls, the onset of puberty was 1.2 years later
than the normal population but the duration of puberty was reduced. The pattern of growth
in girls with treated hypothyroidism is abnormal as growth continues after menarche, at a
time when normal girls have almost stopped growing (Figure 5). During the second year after
menarche patients still have a mean growth velocity of 4.1 cm/year. These data suggest that
juvenile primary hypothyroidism can result in a permanent height deficit and disharmony
between growth and sexual maturation in girls, despite adequate treatment [134].
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Figure 5. The Pattern of linear growth of a girl with juvenile hypothyroidism after treatment (Note the prolonged
growth after menarche and short adult height)
In summary, thyroid hormones act on growth plate, bones and GH-IGF-I axis to modulate
growth. These functions are mediated via many possible mechanisms including direct ac‐
tion on the chondrocytes, osteoblasts and mast cells, as well through interaction with other
hormones and growth factors acting in endocrine, paracrine and autocrine fashions. Early
diagnosis and treatment of infants born with congenital hypothyroidism, through neonatal
screening, results in normal linear growth and attaining full growth potential. However, de‐
layed diagnosis and treatment of congenital hypothyroidism and/or acquired hypothyroid‐
ism may result in partial catch-up growth and compromise final adult height of patients.
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